US Stock MarketDetailed Quotes

GPCR Structure Therapeutics

Watchlist
  • 41.140
  • -0.010-0.02%
Close Nov 1 16:00 ET
  • 41.140
  • 0.0000.00%
Post 17:16 ET
2.35BMarket Cap-23441P/E (TTM)

Structure Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
(Q3)Sep 30, 2022
Total revenue
0
0
0
0
0
0
0
0
0
0
Operating revenue
--0
--0
--0
--0
--0
--0
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
28.20%33.32M
62.93%32.02M
95.53%102.78M
139.23%30.99M
105.98%26.15M
86.15%25.99M
51.71%19.65M
39.43%52.56M
-2.40%12.96M
12.69M
Selling and administrative expenses
71.32%11.27M
74.03%11.34M
99.61%32.67M
138.29%10.95M
144.27%8.63M
74.01%6.58M
46.05%6.51M
90.66%16.37M
36.50%4.6M
--3.53M
-General and administrative expense
71.32%11.27M
74.03%11.34M
99.61%32.67M
138.29%10.95M
144.27%8.63M
74.01%6.58M
46.05%6.51M
90.66%16.37M
36.50%4.6M
--3.53M
Research and development costs
13.60%22.05M
57.43%20.68M
93.69%70.1M
139.74%20.04M
91.21%17.52M
90.66%19.41M
54.67%13.14M
24.33%36.19M
-15.62%8.36M
--9.16M
Operating profit
-28.20%-33.32M
-62.93%-32.02M
-95.53%-102.78M
-139.23%-30.99M
-105.98%-26.15M
-86.15%-25.99M
-51.71%-19.65M
-39.43%-52.56M
2.40%-12.96M
-12.69M
Net non-operating interest income expense
159.65%7.34M
253.62%6.01M
965.31%13.39M
585.79%6.18M
670.20%2.69M
3,617.11%2.83M
2,562.32%1.7M
1,130.33%1.26M
90,200.00%901K
349K
Total other finance cost
-159.65%-7.34M
-253.62%-6.01M
-965.31%-13.39M
-585.79%-6.18M
-670.20%-2.69M
-3,617.11%-2.83M
-2,562.32%-1.7M
-1,130.33%-1.26M
-90,200.00%-901K
---349K
Other net income (expense)
Income before tax
-12.17%-25.98M
-44.89%-26.01M
-74.22%-89.38M
-105.85%-24.82M
-90.03%-23.46M
-66.83%-23.16M
-37.85%-17.95M
-35.66%-51.3M
9.19%-12.06M
-12.34M
Income tax
-55.08%53K
16.00%29K
1,288.24%236K
-73.33%-312K
454.79%405K
84.38%118K
-58.33%25K
-92.64%17K
-322.22%-180K
73K
Net income
-11.83%-26.03M
-44.85%-26.04M
-74.63%-89.62M
-106.34%-24.5M
-92.17%-23.86M
-66.91%-23.28M
-37.41%-17.98M
-34.88%-51.32M
-22.25%-11.88M
-12.42M
Net income continuous Operations
-11.83%-26.03M
-44.85%-26.04M
-74.63%-89.62M
-106.34%-24.5M
-92.17%-23.86M
-66.91%-23.28M
-37.41%-17.98M
-34.88%-51.32M
11.09%-11.88M
---12.42M
Minority interest income
Net income attributable to the parent company
-11.83%-26.03M
-44.85%-26.04M
-74.63%-89.62M
-106.34%-24.5M
-92.17%-23.86M
-66.91%-23.28M
-37.41%-17.98M
-28.28%-51.32M
-1.73%-11.88M
-12.42M
Preferred stock dividends
Other preferred stock dividends
0
0
0
-59.68%1.52M
0
0
Net income attributable to common stockholders
-11.83%-26.03M
-44.85%-26.04M
-69.62%-89.62M
-106.34%-24.5M
-92.17%-23.86M
-50.55%-23.28M
-37.41%-17.98M
-20.73%-52.84M
23.04%-11.88M
-12.42M
Basic earnings per share
10.00%-0.54
24.00%-0.57
-75.89%-2.43
-54.58%-0.48
-29.29%-0.63
1.12%-0.6
-46.10%-0.75
19.56%-1.3816
48.72%-0.3105
-0.4873
Diluted earnings per share
10.00%-0.54
24.00%-0.57
-75.89%-2.43
-54.58%-0.48
-29.29%-0.63
1.12%-0.6
-46.10%-0.75
19.56%-1.3816
48.72%-0.3105
-0.4873
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
--
(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022(Q3)Sep 30, 2022
Total revenue 0000000000
Operating revenue --0--0--0--0--0--0--0--0--0--0
Cost of revenue
Gross profit
Operating expense 28.20%33.32M62.93%32.02M95.53%102.78M139.23%30.99M105.98%26.15M86.15%25.99M51.71%19.65M39.43%52.56M-2.40%12.96M12.69M
Selling and administrative expenses 71.32%11.27M74.03%11.34M99.61%32.67M138.29%10.95M144.27%8.63M74.01%6.58M46.05%6.51M90.66%16.37M36.50%4.6M--3.53M
-General and administrative expense 71.32%11.27M74.03%11.34M99.61%32.67M138.29%10.95M144.27%8.63M74.01%6.58M46.05%6.51M90.66%16.37M36.50%4.6M--3.53M
Research and development costs 13.60%22.05M57.43%20.68M93.69%70.1M139.74%20.04M91.21%17.52M90.66%19.41M54.67%13.14M24.33%36.19M-15.62%8.36M--9.16M
Operating profit -28.20%-33.32M-62.93%-32.02M-95.53%-102.78M-139.23%-30.99M-105.98%-26.15M-86.15%-25.99M-51.71%-19.65M-39.43%-52.56M2.40%-12.96M-12.69M
Net non-operating interest income expense 159.65%7.34M253.62%6.01M965.31%13.39M585.79%6.18M670.20%2.69M3,617.11%2.83M2,562.32%1.7M1,130.33%1.26M90,200.00%901K349K
Total other finance cost -159.65%-7.34M-253.62%-6.01M-965.31%-13.39M-585.79%-6.18M-670.20%-2.69M-3,617.11%-2.83M-2,562.32%-1.7M-1,130.33%-1.26M-90,200.00%-901K---349K
Other net income (expense)
Income before tax -12.17%-25.98M-44.89%-26.01M-74.22%-89.38M-105.85%-24.82M-90.03%-23.46M-66.83%-23.16M-37.85%-17.95M-35.66%-51.3M9.19%-12.06M-12.34M
Income tax -55.08%53K16.00%29K1,288.24%236K-73.33%-312K454.79%405K84.38%118K-58.33%25K-92.64%17K-322.22%-180K73K
Net income -11.83%-26.03M-44.85%-26.04M-74.63%-89.62M-106.34%-24.5M-92.17%-23.86M-66.91%-23.28M-37.41%-17.98M-34.88%-51.32M-22.25%-11.88M-12.42M
Net income continuous Operations -11.83%-26.03M-44.85%-26.04M-74.63%-89.62M-106.34%-24.5M-92.17%-23.86M-66.91%-23.28M-37.41%-17.98M-34.88%-51.32M11.09%-11.88M---12.42M
Minority interest income
Net income attributable to the parent company -11.83%-26.03M-44.85%-26.04M-74.63%-89.62M-106.34%-24.5M-92.17%-23.86M-66.91%-23.28M-37.41%-17.98M-28.28%-51.32M-1.73%-11.88M-12.42M
Preferred stock dividends
Other preferred stock dividends 000-59.68%1.52M00
Net income attributable to common stockholders -11.83%-26.03M-44.85%-26.04M-69.62%-89.62M-106.34%-24.5M-92.17%-23.86M-50.55%-23.28M-37.41%-17.98M-20.73%-52.84M23.04%-11.88M-12.42M
Basic earnings per share 10.00%-0.5424.00%-0.57-75.89%-2.43-54.58%-0.48-29.29%-0.631.12%-0.6-46.10%-0.7519.56%-1.381648.72%-0.3105-0.4873
Diluted earnings per share 10.00%-0.5424.00%-0.57-75.89%-2.43-54.58%-0.48-29.29%-0.631.12%-0.6-46.10%-0.7519.56%-1.381648.72%-0.3105-0.4873
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ----Unqualified Opinion--------Unqualified Opinion----

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data

Concept Weight Loss Drugs
Weight Loss Drugs
Intraday-0.73%